Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Biobusiness Briefs
  • Published:

Patent watch

Microscale implantable drug delivery systems: emerging IP strategies

Nature Reviews Drug Discovery volume 15, pages 740–741 (2016)Cite this article

Subjects

Microscale implantable drug delivery systems (IDDSs) have advanced the control of drug delivery parameters, providing better disease control through more accurate, targeted and less painful drug delivery. Numerous physical designs, actuation and control techniques for microscale IDDSs are being explored. Microscale IDDSs have been effective in treating diseases and improving patient compliance and quality of life for osteoporosis and have the potential to reach other disease areas such as diabetes, neurological disorders and contraception (Sci. Transl Med. 4, 122ra21; 2012) (see Further information).

Successful commercial development of microscale IDDSs will rely on strategic partnerships and cooperation between pharmaceutical and medical device companies to leverage resources and implement therapeutic improvements. Developers must not only demonstrate the clinical safety and efficacy of their technologies, but also successfully grow and protect their intellectual property (IP) within the competitive landscape through strategic IP decisions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Intellectual property landscape surrounding micro- and nano- scale implantable drug delivery systems.

Author information

Authors and Affiliations

  1. Dana Daukss and Kennyn Statler are at Global Prior Art Inc., 21 Milk Street, Boston, Massachusetts 02109, USA.,

    Dana Daukss & Kennyn Statler

Authors
  1. Dana Daukss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kennyn Statler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kennyn Statler.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Daukss, D., Statler, K. Microscale implantable drug delivery systems: emerging IP strategies. Nat Rev Drug Discov 15, 740–741 (2016). https://doi.org/10.1038/nrd.2016.210

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2016.210

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research